探討部分磷酸根甲基化之反義去氧核醣核苷酸調控核糖核酸能力之影響- 以綠色螢光蛋白、人類端粒反轉錄酶信使核醣核酸與人類端粒酶核酸模板為例

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：53

、訪客IP：3.133.135.8

姓名

鄔子凡(Tzu-Fan Wu) 查詢紙本館藏

畢業系所

化學工程與材料工程學系

論文名稱

探討部分磷酸根甲基化之反義去氧核醣核苷酸調控核糖核酸能力之影響- 以綠色螢光蛋白、人類端粒反轉錄酶信使核醣核酸與人類端粒酶核酸模板為例
(Investigation of the Impact of Partially Methylated Methyl Phosphotriester Antisense Oligodeoxynucleotides on the Regulation of RNA- Case studies on green fluorescent protein, human telomerase reverse transcriptase messenger RNA, and human telomerase RNA template.)

相關論文

★ 類澱粉胜肽聚集行為之電腦模擬	★ 溶解度參數計算及量測於HPLC純化胜肽程序之最佳化研究
★ 利用恆溫滴定微卡計量測蛋白質分子於溶液中之第二維里係數與自我聚集之行為	★ 利用SPRi探討中性DNA探針相較於一般DNA探針在低鹽雜交環境下之優勢
★ 矽奈米線場效電晶體多點之核酸檢測研究	★ 使用不帶電中性核酸探針於矽奈米線場效電晶體檢測去氧核醣核酸與微核醣核酸之研究
★ 運用nDNA 修飾引子於PCR及qPCR平台以提升專一性之研究	★ 設計中性DNA引子及探針以提升PCR與qPCR專一性之研究
★ 使用中性不帶電去氧核醣核酸探針於矽奈米線場效電晶體檢測微核醣核酸之研究	★ 使用不帶電中性核酸探針於原位雜交技術檢測微核醣核酸之研究
★ 設計不帶電中性核酸探針於矽奈米線場效電晶體來改善富含GC鹼基核醣核酸之檢測專一性	★ 合成5’-MeNPOC-2’-deoxynucleoside p-methoxy phosphoramidite以作為應用於原位合成之新穎性中性核苷酸之研究
★ 立體紙基外泌體核酸萃取裝置應用於檢測不同微環境下癌細胞所釋放之外泌體與外泌體微小核醣核酸之表現量	★ 利用抗原結合區段之抗體片段探針於矽奈米線場效電晶體來改善抗原檢測濃度極限之研究
★ 利用表面電漿共振影像儀驗證最適化之抗非專一性吸附場效電晶體表面於血清環境下之免疫測定	★ 使用混合自組裝單層膜於矽奈米線場效電晶體檢測微小核醣核酸之研究

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

至系統瀏覽論文 (2026-8-19以後開放)

摘要(中)

反義寡核苷酸（Antisense oligonucleotides, ASOs）是設計用來特異性地與信使RNA（messenger RNA, mRNA）互補序列結合的合成單鏈DNA或RNA分子。然而，未經修飾的DNA ASOs通常顯示出低親和力和生物不穩定性。在本研究中，我們引入了一種稱為中性DNA（neutralized DNA, nDNA）的DNA ASO。這些ASOs是通過對DNA結構內的磷酸二酯鍵的磷酸基進行甲基化修飾，化學合成的位點特異性磷酸甲基三酯（methyl phosphotriester, MTPE）鍵。DNA磷酸骨架的負電荷被中和，從而減少了核酸雙鏈之間的靜電排斥，並提高了親和力和穩定性。為了將nDNA ASOs輸送到細胞中，我們使用了多孔性二氧化矽奈米粒子（mesoporous silica nanoparticles, MSN）作為載體。
在癌症細胞中，部分致癌基因（Oncogene）因為細胞基因突變導致過量表達，例如c-Myc、Survivin，造成細胞代謝方式改變以及異常增殖。此外，Greider和Blackburn在1985年發現的端粒酶（telomerase），通過維持染色體端粒（telomere）的長度，使細胞變得永生。端粒酶在許多癌細胞中表達，但在正常人體體細胞中幾乎不表達。因此，這些在癌細胞特有的過量表達mRNA或蛋白質，成為癌症治療中的良好標靶。
本研究分為兩部分。在第一部分中，為了評估nDNA ASO對長鏈RNA的調控能力，我們使用表達報告基因（reporter gene）增強綠色螢光蛋白（enhanced green fluorescent protein, eGFP）mRNA的直腸癌細胞HCT-116 eGFP，評估不同數量的MTPE修飾的nDNA抑制eGFP mRNA的效率。隨後，我們選擇人類端粒酶逆轉錄酶mRNA（human telomerase reversed transcriptase mRNA, hTERT mRNA）與人類端粒酶核酸模板（Human Telomerase RNA Template, hTR）作為內源性基因抑制的目標。然而，長鏈RNA分子中存在二級、三級結構，這些立體結構可能影響nDNA ASO對目標RNA抑制能力。在本研究中，eGFP nDNA ASO序列參考過去研究所使用的siRNA序列，hTERT nDNA ASO參考鎖核酸（Locked nucleic acid, LNA） gapmer序列，而hTR nDNA ASO則是參考磷硫酸脂（Phosphorothioates, PS）ASO序列，篩選出合適的nDNA ASO序列。
nDNA ASO藉由序列互補與目標RNA結合，使目標mRNA無法被核醣體轉譯出蛋白質。結果顯示，當目標序列是eGFP mRNA和hTERT mRNA，nDNA ASO皆無法有效地抑制；而目標序列是hTR時，nDNA ASO可以成功抑制hTR逆轉錄。這些siRNA和核酸類似物的RNA干擾（RNA interference, RNAi）機制不同，其分子對目標核酸序列親和力不同，導致對於相同核酸序列之抑制能力也隨之不同。
在本研究第二部分中，我們藉由調整hTR nDNA ASO的nDNA修飾位置與hTR nDNA ASO序列長度，來看對於hTR逆轉錄抑制能力之影響。在nDNA修飾位置上，我們發現當nDNA修飾在對應hTR環結構上，展現出更佳的抑制能力，此結果也呼應Buck的nDNA抑制HIV-1 RNA研究。進一步我們根據hTR環結構相對位置調整nDNA ASO長度，發現延長nDNA ASO並包覆環結構反而降低nDNA ASO抑制能力；而將nDNA ASO序列縮短並只包覆環結構，則能夠提升nDNA ASO的抑制能力，並且隨著nDNA修飾數量越多，抑制能力越好。
本研究結果揭露利用部分磷酸根甲基化nDNA ASO在HCT-116細胞與HCT-116 eGFP細胞內調控長鏈RNA，其目標RNA結構如何影響nDNA ASO調控能力，並初步比較相同目標序列siRNA、LNA gapmer ASO與PS ASO，nDNA ASO對這些目標序列的抑制能力，期望能用作未來用於其他致癌基因治療之nDNA ASO設計上參考。

摘要(英)

ASOs are synthetic single-stranded DNA or RNA molecules designed to bind specifically to complementary sequences of messenger RNA (mRNA). However, unmodified DNA-based ASOs often exhibit low affinity and bio-instability. In this study, we introduced a class of DNA-based ASO called neutralized DNA (nDNA). These ASOs are chemically synthesized with site-specific internucleoside methyl phosphotriester (MPTE) linkages, achieved by methylating the phosphate groups of the phosphodiester bonds within the DNA structure. The negatively charged DNA phosphodiester backbone is neutralized, thus reducing electrostatic repulsion between nucleic acid double strands and leading to enhanced affinity and stability. To deliver nDNA ASOs into cells, mesoporous silica nanoparticle (MSN) was used as the carrier.

In cancer cells, certain oncogenes are overexpressed due to genetic mutations, such as c-Myc and Survivin, leading to changes in cell metabolism and abnormal proliferation. Additionally, telomerase, discovered by Greider and Blackburn in 1985, maintains chromosome telomere length, allowing cells to become immortal. Telomerase is expressed in many cancer cells but hardly in normal human somatic cells. Therefore, these overexpressed mRNAs specific to cancer cells become good targets for cancer treatment.

This study is divided into two parts. In the first part, to evaluate the regulatory ability of nDNA ASO on long-chain mRNA, we used HCT-116 eGFP, HCT-116 cells expressing reporter gene enhanced green fluorescent protein (eGFP) mRNA, to assess the efficiency of different numbers of MTPE-modified nDNA in inhibiting eGFP mRNA. Subsequently, we selected human telomerase reverse transcriptase mRNA (hTERT mRNA) and human telomerase RNA template (hTR) as targets for endogenous gene inhibition. However, the secondary and tertiary structures in long-chain RNA molecules might affect the inhibitory ability of nDNA ASO on target RNA. In this study, the eGFP nDNA ASO sequence was referenced from siRNA sequences used in previous research, the hTERT nDNA ASO was based on Locked Nucleic Acid (LNA) gapmer sequences, and the hTR nDNA ASO was referenced from phosphorothioate (PS) ASO sequences, selecting suitable nDNA ASO sequences. The different mechanisms of RNAi-induced enzyme degradation and varying molecular affinities for the target sequences lead to different inhibitory capabilities of RNAi on the same sequence.

Previous research by Buck on HIV-1 RNA inhibition indicated that nDNA sequences have better inhibitory effects on RNA sequences with loop secondary structures, and the more free bases on the loop, the higher the nDNA inhibition capacity. In the second part, we used RNA fold analysis to examine the hTR structure and found that modifying nDNA at positions corresponding to the hTR loop structure can enhance inhibition. However, extending the ASO 5′ end to fully cover the hTR loop structure reduced the inhibitory effect of nDNA ASO on hTR. We hypothesize that extending the ASO sequence leads to more DNA-RNA hybrid formation, resulting in more B-form to A-form transitions and decreased sequence affinity. Shortening the ASO 3′ end to cover only the hTR loop target sequence increases the nDNA ASO inhibitory ability, and more nDNA modifications further improve the nDNA ASO′s ability to inhibit hTR.

The results provide insights into the design considerations of nDNA ASOs, suggesting that the selection of target sequences should avoid regions rich in secondary and tertiary structures or RNA-binding protein regions. By using RNA fold analysis and referencing previously successful ASO sequences, suitable nDNA ASO sequences can be selected. Once the appropriate nDNA ASO sequences are chosen, the sequence length and nDNA modification locations relative to the target sequence loop structure can influence the nDNA ASO′s inhibitory ability. This information can reduce the labor and time costs in future nDNA ASO design efforts in our laboratory, leading to the discovery of effective nDNA ASOs for inhibiting various oncogenes.

關鍵字(中)

★ 反義寡核苷酸
★ 核酸類似物

關鍵字(英)

★ antisense oligonucleotide
★ nucleic acid analogue

論文目次

摘要 i
Abstract iv
致謝 vi
圖目錄 xiv
表目錄 xviii
一、緒論 1
二、文獻回顧 3
2-1 癌症 3
2-1-1 癌症起因 3
2-1-2 癌細胞中的異常mRNA表達 4
2-1-3 基因癌症治療 5
2-2 信使核糖核酸 5
2-3 端粒酶 7
2-3-1 端粒酶過表達與癌症 9
2-4 基因靜默 12
2-4-1 RNA干擾 12
2-4-2 反義寡核苷酸 14
2-4-3 CRISPR/Cas9 16
2-5 核酸雜交反應 18
2-5-1 核酸二級結構、立體結構 18
2-5-1-1 核酸二級結構預測 20
2-5-2 核酸類似物 22
2-5-2-1 第一代核酸類似物 22
2-5-2-2 第二代核酸類似物 23
2-5-2-3 第三代核酸類似物 25
2-5-3 中性去氧核醣核酸 28
2-5-3-1 nDNA在長鏈RNA的調控挑戰 33
2-6 基因載體 35
2-6-1 基因載體介紹 35
2-6-2 多孔性二氧化矽奈米粒子 36
三、實驗方法與儀器設備 40
3-1 實驗藥品 40
3-1-1 細胞培養 40
3-1-2 細胞轉染 40
3-1-3 反義寡核苷酸探針序列設計 40
3-1-5 細胞毒性分析 42
3-1-6 洋菜凝膠電泳（Agarose gel） 42
3-1-7 即時聚合酶鏈式反應 42
3-1-8 MSN DNA probe藥物釋放曲線 43
3-1-9 細胞萃取RNA 43
3-2 儀器設備 43
3-3 實驗方法 44
3-3-1 細胞解凍 44
3-3-2 細胞冷凍保存 45
3-3-3 細胞培養 46
3-3-4 MSN載體吸附DNA 47
3-3-5 細胞轉染 47
3-3-6 細胞毒性分析 48
3-3-7 洋菜凝膠電泳（Agarose gel） 48
3-3-8 細胞萃取RNA 49
3-3-9 逆轉錄即時聚合酶鏈式反應（RT-qPCR） 50
3-3-10 綠螢光蛋白表達抑制實驗 53
四、結果與討論 54
4-1 多孔性二氧化矽奈米粒子裝載反義寡核苷酸探針系統 54
4-1-1 多孔性二氧化矽奈米粒子裝載效率（Loading efficiency） 55
4-1-2 in-vitro 多孔性二氧化矽奈米粒子ASO藥物釋放曲線 58
4-2 細胞毒性分析 62
4-2-1 MSN裝載ASO系統細胞毒性分析 63
4-3 反義寡核苷酸探針對於mRNA抑制能力 64
4-3-1 不同nDNA數量修飾的反義寡核苷酸探針修飾對於eGFP 螢光蛋白表現量變化 65
4-3-2 不同nDNA數量修飾的反義寡核苷酸探針修飾對於eGFP mRNA轉譯的抑制能力 69
4-3-3 不同nDNA數量修飾的反義寡核苷酸探針修飾對於hTERT mRNA的抑制能力 70
4-3-4 nDNA在長鏈RNA靜默的挑戰 72
4-4 nDNA ASO對於hTR抑制能力 75
4-4-1 不同nDNA位置修飾的反義寡核苷酸探針修飾對於hTR的抑制能力 76
4-4-2 使用長hTR ASO-L序列長度確認對於hTR抑制能力之影響 78
4-4-3 使用短hTRS probe序列確認對於hTR抑制能力之影響 80
4-4-4 nDNA ASO與其他RNA干擾、核酸類似物機制比較 82
五、結論 84
六、未來展望 86
七、參考文獻 87

參考文獻

1. Haisma, H., Endosomal escape pathways for delivery of biologicals. Human Gene Therapy, 2011. 22: p. A14-A14.
2. Li, K., et al., Microstructure and Properties of Poly(Ethylene Glycol)-Segmented Polyurethane Antifouling Coatings after Immersion in Seawater. Polymers, 2021. 13: p. 573.
3. Inoue, J. and J. Inazawa, Cancer-associated miRNAs and their therapeutic potential. Journal of Human Genetics, 2021. 66(9): p. 937-945.
4. Miller, D.M., et al., c-Myc and Cancer Metabolism. Clinical Cancer Research, 2012. 18(20): p. 5546-5553.
5. Dieckmann, A., et al., A Sensitive <i>In Vitro</i> Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides. MOLECULAR THERAPY-NUCLEIC ACIDS, 2018. 10: p. 45-54.
6. Kasuya, T., et al., Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides. Scientific Reports, 2016. 6(1): p. 30377.
7. Lu, F., et al., Size Effect on Cell Uptake in Well-Suspended, Uniform Mesoporous Silica Nanoparticles. Small, 2009. 5(12): p. 1408-1413.
8. Chen, J.L. and C.W. Greider, Functional analysis of the pseudoknot structure in human telomerase RNA. Proc Natl Acad Sci U S A, 2005. 102(23): p. 8080-5; discussion 8077-9.
9. Horvath, P. and R. Barrangou, CRISPR/Cas, the immune system of bacteria and archaea. Science, 2010. 327(5962): p. 167-70.
10. Khawar, I.A., J.H. Kim, and H.J. Kuh, Improving drug delivery to solid tumors: Priming the tumor microenvironment. Journal of Controlled Release, 2015. 201: p. 78-89.
11. Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309-14.
12. Altieri, D.C., Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 2003. 22(53): p. 8581-9.
13. Sah, N.K., et al., Structural, functional and therapeutic biology of survivin. Cancer Lett, 2006. 244(2): p. 164-71.
14. MULLER, H.J., The remaking of chromosomes. Collecting net, 1938. 8: p. 198.
15. McClintock, B., The Behavior in Successive Nuclear Divisions of a Chromosome Broken at Meiosis. Proc Natl Acad Sci U S A, 1939. 25(8): p. 405-16.
16. Kipling, D. and H.J. Cooke, Hypervariable ultra-long telomeres in mice. Nature, 1990. 347(6291): p. 400-2.
17. Moyzis, R.K., et al., A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A, 1988. 85(18): p. 6622-6.
18. Greider, C.W. and E.H. Blackburn, Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell, 1985. 43(2 Pt 1): p. 405-13.
19. Chin, L., et al., p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell, 1999. 97(4): p. 527-38.
20. Counter, C.M., et al., Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. Embo j, 1992. 11(5): p. 1921-9.
21. Kim, N.W., et al., Specific association of human telomerase activity with immortal cells and cancer. Science, 1994. 266(5193): p. 2011-5.
22. Buseman, C.M., W.E. Wright, and J.W. Shay, Is telomerase a viable target in cancer? Mutat Res, 2012. 730(1-2): p. 90-7.
23. Djojosubroto, M.W., et al., Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology, 2005. 42(5): p. 1127-36.
24. Dikmen, Z.G., et al., In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res, 2005. 65(17): p. 7866-73.
25. Burchett, K.M., Y. Yan, and M.M. Ouellette, Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One, 2014. 9(1): p. e85155.
26. Relitti, N., et al., Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Curr Top Med Chem, 2020. 20(6): p. 433-457.
27. Lam, J.K., et al., siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids, 2015. 4(9): p. e252.
28. Svoboda, P., Key Mechanistic Principles and Considerations Concerning RNA Interference. Front Plant Sci, 2020. 11: p. 1237.
29. Stephenson, M.L. and P.C. Zamecnik, Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A, 1978. 75(1): p. 285-8.
30. Roehr, B., Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care, 1998. 4(10): p. 14-6.
31. Egli, M. and M. Manoharan, Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Research, 2023. 51(6): p. 2529-2573.
32. Bauman, J., N. Jearawiriyapaisarn, and R. Kole, Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides, 2009. 19(1): p. 1-13.
33. Ishino, Y., et al., Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol, 1987. 169(12): p. 5429-33.
34. Tang, T.H., et al., Identification of 86 candidates for small non-messenger RNAs from the archaeon Archaeoglobus fulgidus. Proc Natl Acad Sci U S A, 2002. 99(11): p. 7536-41.
35. Mojica, F.J., et al., Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol, 2005. 60(2): p. 174-82.
36. Barrangou, R., et al., CRISPR provides acquired resistance against viruses in prokaryotes. Science, 2007. 315(5819): p. 1709-12.
37. Jinek, M., et al., A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 2012. 337(6096): p. 816-821.
38. Feng, B., et al., Hydrophobic catalysis and a potential biological role of DNA unstacking induced by environment effects. Proc Natl Acad Sci U S A, 2019. 116(35): p. 17169-17174.
39. Chaires, J.B., Calorimetry and thermodynamics in drug design. Annu Rev Biophys, 2008. 37: p. 135-51.
40. Mergny, J.L. and L. Lacroix, Analysis of thermal melting curves. Oligonucleotides, 2003. 13(6): p. 515-37.
41. Herbert, A., et al., Special Issue: A, B and Z: The Structure, Function and Genetics of Z-DNA and Z-RNA. Int J Mol Sci, 2021. 22(14).
42. Lu, Y.F., et al., IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep, 2015. 5: p. 16037.
43. Ma, H., et al., Exploring the energy landscape of a small RNA hairpin. J Am Chem Soc, 2006. 128(5): p. 1523-30.
44. Mathews, D.H., et al., Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A, 2004. 101(19): p. 7287-92.
45. Kulkarni, J.A., et al., The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021. 16(6): p. 630-643.
46. Krieg, A.M. and C.A. Stein, Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev, 1995. 5(4): p. 241.
47. Altmann, K.H., et al., Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans, 1996. 24(3): p. 630-7.
48. Crooke, S.T., et al., Antisense technology: an overview and prospectus. Nat Rev Drug Discov, 2021. 20(6): p. 427-453.
49. Yu, R.Z., et al., Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos, 2007. 35(3): p. 460-8.
50. Hovingh, K., J. Besseling, and J. Kastelein, Efficacy and safety of mipomersen sodium (Kynamro). Expert opinion on drug safety, 2013. 12(4): p. 569-579.
51. Obika, S., et al., Synthesis of 2′-O, 4′-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3,-endo sugar puckering. Tetrahedron Letters, 1997. 38(50): p. 8735-8738.
52. Campbell, M.A. and J. Wengel, Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev, 2011. 40(12): p. 5680-9.
53. Burel, S.A., et al., Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. NUCLEIC ACIDS RESEARCH, 2016. 44(5): p. 2093-2109.
54. Genderen, M., L.H. Koole, and H. Buck, Hybridization of phosphate‐methylated DNA and natural oligonucleotides. Implications for protein‐induced DNA duplex destabilization. Recueil des Travaux Chimiques des Pays-Bas, 2010. 108: p. 28-35.
55. Buck, H.M., et al., Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity. Science, 1990. 248(4952): p. 208-12.
56. 陳奕儒, 探討中性DNA與一般DNA雜交反應熱力學與結合機制之研究, in 化學工程與材料工程學系. 2016, 國立中央大學: 桃園縣. p. 115.
57. 張晴雯, 部分磷酸根甲基化之反義去氧核醣核酸探針與微小核糖核酸雜交靈敏度與專一性之研究, in 化學工程與材料工程學系. 2022, 國立中央大學: 桃園縣. p. 123.
58. Tian, B., et al., The double-stranded-RNA-binding motif: interference and much more. Nat Rev Mol Cell Biol, 2004. 5(12): p. 1013-23.
59. Hagedorn, P.H., et al., Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Res, 2017. 45(5): p. 2262-2282.
60. Kretschmer-Kazemi Far, R. and G. Sczakiel, The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res, 2003. 31(15): p. 4417-24.
61. Lundstrom, K. and T. Boulikas, Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat, 2003. 2(5): p. 471-86.
62. Watermann, A. and J. Brieger, Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer. Nanomaterials (Basel), 2017. 7(7).
63. Ashley, C.E., et al., The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater, 2011. 10(5): p. 389-97.
64. Albanese, A., P.S. Tang, and W.C. Chan, The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng, 2012. 14: p. 1-16.
65. Na, H.K., et al., Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small, 2012. 8(11): p. 1752-61.
66. 吳佳嶸, 以磷酸根甲基化之反義去氧核醣核酸探針藉由多孔性二氧化矽奈米粒子作為載體進行基因靜默調控之研究, in 化學工程與材料工程學系. 2023, 國立中央大學: 桃園縣. p. 128.
67. Meng, H., et al., Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano, 2013. 7(2): p. 994-1005.
68. Sun, H., et al., Visualizing the down-regulation of hTERT mRNA expression using gold-nanoflare probes and verifying the correlation with cancer cell apoptosis. Analyst, 2019. 144(9): p. 2994-3004.
69. Chang, J.-H., et al., Dual delivery of siRNA and plasmid DNA using mesoporous silica nanoparticles to differentiate induced pluripotent stem cells into dopaminergic neurons. Journal of Materials Chemistry B, 2017. 5(16): p. 3012-3023.
70. Sherbet, G.V., M.S. Lakshmi, and F. Cajone, Isoelectric characteristics and the secondary structure of some nucleic acids. Biophysics of structure and mechanism, 1983. 10(3): p. 121-128.
71. Ishiyama, M., et al., A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull, 1996. 19(11): p. 1518-20.
72. Green, K.M., et al., Non-canonical initiation factors modulate repeat-associated non-AUG translation. Human Molecular Genetics, 2022. 31(15): p. 2521-2534.
73. Blasco, M.A., et al., Functional characterization and developmental regulation of mouse telomerase RNA. Science, 1995. 269(5228): p. 1267-70.
74. Yakovchuk, P., E. Protozanova, and M.D. Frank-Kamenetskii, Base-stacking and base-pairing contributions into thermal stability of the DNA double helix. NUCLEIC ACIDS RESEARCH, 2006. 34(2): p. 564-574.
75. El Boujnouni, N., et al., Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1. Mol Ther Nucleic Acids, 2023. 32: p. 622-636.

指導教授

陳文逸(Wen-Yih Chen)

審核日期

2024-8-20

推文